Zacks: Analysts Expect Viveve Medical Inc (VIVE) to Announce -$0.36 EPS

Equities research analysts expect that Viveve Medical Inc (NASDAQ:VIVE) will announce earnings of ($0.36) per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Viveve Medical’s earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.41). Viveve Medical posted earnings per share of ($0.53) during the same quarter last year, which suggests a positive year-over-year growth rate of 32.1%. The business is expected to announce its next quarterly earnings results on Thursday, March 21st.

According to Zacks, analysts expect that Viveve Medical will report full-year earnings of ($1.52) per share for the current year, with EPS estimates ranging from ($1.63) to ($1.39). For the next year, analysts forecast that the company will report earnings of ($1.06) per share, with EPS estimates ranging from ($1.32) to ($0.84). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Viveve Medical.

Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.06). The business had revenue of $4.82 million for the quarter, compared to the consensus estimate of $4.60 million. Viveve Medical had a negative net margin of 239.33% and a negative return on equity of 551.85%.

Separately, ValuEngine lowered shares of Viveve Medical from a “buy” rating to a “hold” rating in a report on Monday, July 30th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $8.75.

Viveve Medical stock opened at $2.32 on Wednesday. The stock has a market capitalization of $103.60 million, a PE ratio of -1.10 and a beta of -0.25. The company has a debt-to-equity ratio of 3.42, a current ratio of 4.41 and a quick ratio of 4.00. Viveve Medical has a 12-month low of $1.60 and a 12-month high of $5.40.

Several institutional investors have recently added to or reduced their stakes in the company. Granahan Investment Management Inc. MA lifted its holdings in shares of Viveve Medical by 117.8% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 792,607 shares of the company’s stock worth $2,156,000 after acquiring an additional 428,708 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Viveve Medical by 11.0% in the 2nd quarter. Marshall Wace LLP now owns 441,279 shares of the company’s stock worth $1,200,000 after acquiring an additional 43,842 shares during the last quarter. Paloma Partners Management Co bought a new stake in shares of Viveve Medical in the 2nd quarter worth about $268,000. RTW Investments LP lifted its holdings in shares of Viveve Medical by 11.9% in the 2nd quarter. RTW Investments LP now owns 2,861,023 shares of the company’s stock worth $7,782,000 after acquiring an additional 303,464 shares during the last quarter. Finally, Nantahala Capital Management LLC lifted its holdings in shares of Viveve Medical by 38.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 3,948,132 shares of the company’s stock worth $10,739,000 after acquiring an additional 1,100,928 shares during the last quarter. Hedge funds and other institutional investors own 61.98% of the company’s stock.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.

Further Reading: How Do Tariffs Affect Trade Balances?

Get a free copy of the Zacks research report on Viveve Medical (VIVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply